Timing of eculizumab therapy for C3 glomerulonephritis (Q35891599)

11 August 2017

Timing of eculizumab therapy for C3 glomerulonephritis (English)

1 reference

11 August 2017

1 reference

C3 glomerulonephritis

1 reference

Alberto Ortiz

2

0 references

author name string

Laura Rodriguez-Osorio

series ordinal

1

1 reference

11 August 2017

27 July 2015

1 reference

Clinical kidney journal / an academic journal of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association)

11 August 2017

1 reference

11 August 2017

8

1 reference

11 August 2017

4

1 reference

11 August 2017

449-452

1 reference

Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Remission of aHUS neurological damage with eculizumab

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Success of eculizumab in the treatment of atypical hemolytic uremic syndrome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Blockade of alternative complement pathway in dense deposit disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

A case of atypical hemolytic uremic syndrome successfully treated with eculizumab

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

C3 glomerulopathy: consensus report

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

C3 glomerulopathies. A new perspective on glomerular diseases.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Eculizumab for dense deposit disease and C3 glomerulonephritis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4515909

Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy

11 July 2018

1 reference

12 December 2020

Eculizumab for treatment of rapidly progressive C3 glomerulopathy

1 reference

12 December 2020

Rituximab fails where eculizumab restores renal function in C3nef-related DDD

1 reference

12 December 2020

A case of C3 glomerulonephritis successfully treated with eculizumab

1 reference

12 December 2020

Identifiers

DOI

10.1093/CKJ/SFV065

1 reference

11 August 2017

1 reference

PMC publication ID

4515909

11 August 2017

PubMed publication ID

26251715

1 reference

PMC publication ID

4515909